These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7523779)

  • 1. Thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator, in a photochemically induced platelet-rich thrombosis model.
    Kawasaki T; Kaku S; Takenaka T; Yanagi K; Ohshima N
    J Cardiovasc Pharmacol; 1994 Jun; 23(6):884-9. PubMed ID: 7523779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental model of carotid artery thrombosis in rats and the thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator.
    Kawasaki T; Kawamura S; Katoh S; Takenaka T
    Jpn J Pharmacol; 1993 Oct; 63(2):135-42. PubMed ID: 8283822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis.
    Kawasaki T; Katoh M; Kaku S; Gushima H; Takenaka T; Yui Y; Kawai C
    Jpn J Pharmacol; 1993 Sep; 63(1):9-16. PubMed ID: 8271535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombolysis with intracoronary administration of YM866, a novel modified tissue-type plasminogen activator, in a canine model of coronary artery thrombosis.
    Kawasaki T; Katoh M; Kaku S; Gushima H; Takenaka T; Yui Y; Kawai C
    Jpn J Pharmacol; 1993 Nov; 63(3):319-25. PubMed ID: 8107325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of a mutant tissue-type plasminogen activator, YM866, with a tissue-type plasminogen activator in a canine model of femoral arterial thrombosis.
    Kawasaki T; Kaku S; Sakai Y; Takenaka T
    J Pharm Pharmacol; 1996 Oct; 48(10):1041-8. PubMed ID: 8953506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YM866, a novel modified tissue-type plasminogen activator, affects left ventricular function and myocardial infarct development in dogs with coronary artery thrombi.
    Suzuki M; Funatsu T; Tanaka H; Usuda S
    Jpn J Pharmacol; 1998 Jul; 77(3):177-83. PubMed ID: 9717764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.
    Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Mizuo H; Yuzuriha T; Yui Y; Kawai C
    J Cardiovasc Pharmacol; 1991 May; 17(5):738-46. PubMed ID: 1713988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A thrombosis model for evaluating thrombolytic agents in the guinea-pig: comparison of t-PA, scu-PA and a novel thrombolytic agent, staphylokinase, on thrombolytic activity.
    Hirata Y; Umemura K; Takiguchi Y; Uematsu T; Nakashima M
    Blood Coagul Fibrinolysis; 1993 Aug; 4(4):569-75. PubMed ID: 7692999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow.
    Graham DA; Huang TC; Keyt BA; Alevriadou BR
    Ann Biomed Eng; 1998; 26(4):712-24. PubMed ID: 9662163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model.
    Nishiyama H; Umemura K; Saniabadi AR; Takiguchi Y; Uematsu T; Nakashima M
    Eur J Pharmacol; 1994 Oct; 264(2):191-8. PubMed ID: 7851482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA; Nichols WW; Saldeen TG; Mehta JL
    Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombolysis of canine femoral artery thrombus by a novel modified tissue-type plasminogen activator (E6010).
    Suzuki N; Suzuki S; Nagaoka N; Mizuo H; Yuzuriha T; Yoshitake S; Kanmatuse K
    Jpn J Pharmacol; 1994 Jul; 65(3):257-63. PubMed ID: 7799526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice.
    Kawasaki T; Dewerchin M; Lijnen HR; Vermylen J; Hoylaerts MF
    Blood; 2000 Jul; 96(1):153-60. PubMed ID: 10891445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel platelet-rich arterial thrombosis model in rabbits. Simple, reproducible, and dynamic real-time measurement by using double-opposing inverted-sutures model.
    Shieh SJ; Chiu HY; Shi GY; Wu CM; Wang JC; Chen CH; Wu HL
    Thromb Res; 2001 Sep; 103(5):363-76. PubMed ID: 11553369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
    Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanism of action of newer thrombolytic agents.
    Collen D
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):11B-15B. PubMed ID: 3117858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombolytic effect of a plasminogen-plasminogen activator chimera in a photochemically induced thrombosis (PIT) model.
    Matsuno H; Uematsu T; Nakashima M
    Br J Pharmacol; 1993 Dec; 110(4):1278-9. PubMed ID: 8306063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.